Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Martin Tolar, Jorge Conde

Premium

Knome announced that Martin Tolar will become the firm's CEO, replacing Jorge Conde, who will become chief strategy officer and continue to serve on the board of directors. Previously, Tolar served as CEO of Normoxys, where he helped advance the company's cancer therapeutics to clinical development. He has also served as chief scientific officer and chief business officer at CoMentis, and has held a variety of positions at Pfizer in its clinical development, strategic partnerships, and business development divisions.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.